News
By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...
It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...
India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...
AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...
The stock's fall snapped a three-day winning streak.
The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...
Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...
AbbVie Inc. defeated class action claims it misled investors about the role kickbacks played in the success of its arthritis ...
With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...
This was the stock's third consecutive day of gains.
A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to ...
AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results